{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:15:37Z","timestamp":1773422137164,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T00:00:00Z","timestamp":1354233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s10072-012-1251-2","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T14:13:13Z","timestamp":1354198393000},"page":"621-627","source":"Crossref","is-referenced-by-count":21,"title":["Arterial hypertension, a tricky side of Parkinson\u2019s disease: physiopathology and therapeutic features"],"prefix":"10.1007","volume":"34","author":[{"given":"Alberto","family":"Mazza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ravenni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Casiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pauletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,30]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","volume":"371","author":"CM Lawes","year":"2008","unstructured":"Lawes CM (2008) Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513\u20131518","journal-title":"Lancet"},{"key":"1251_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1532-5415.2011.03317.x","volume":"59","author":"A Gangavati","year":"2011","unstructured":"Gangavati A, Hajjar I, Quach L et al (2011) Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 59:383\u2013389","journal-title":"J Am Geriatr Soc"},{"key":"1251_CR3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000054770","volume":"20","author":"A Paganini-Hill","year":"2001","unstructured":"Paganini-Hill A (2001) Risk factors for Parkinson\u2019s disease: the leisure world cohort study. Neuroepidemiology 20:118\u2013124","journal-title":"Neuroepidemiology"},{"key":"1251_CR4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000026185","volume":"17","author":"SJ McCann","year":"1998","unstructured":"McCann SJ, LeCouteur DG, Green AC et al (1998) The epidemiology of Parkinson\u2019s disease in an Australian population. Neuroepidemiology 17:310\u2013317","journal-title":"Neuroepidemiology"},{"key":"1251_CR5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1017\/S0317167100052835","volume":"28","author":"YO Herishanu","year":"2001","unstructured":"Herishanu YO, Medvedovski M, Goldsmith JR et al (2001) A case-control study of Parkinson\u2019s disease in urban population of southern Israel. Can J Neurol Sci 28:144\u2013147","journal-title":"Can J Neurol Sci"},{"key":"1251_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jns.2003.07.006","volume":"216","author":"EK Tan","year":"2003","unstructured":"Tan EK, Tan C, Fook-Chong SM et al (2003) Dose dependent protective effect of coffee, tea, and smoking in Parkinson\u2019s disease: a study in ethnic Chinese. J Neurol Sci 216:163\u2013167","journal-title":"J Neurol Sci"},{"key":"1251_CR7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.43.6.1173","volume":"43","author":"KM Semchuk","year":"1993","unstructured":"Semchuk KM, Love EJ, Lee RG (1993) Parkinson\u2019s disease: a test of the multifactorial etiologic hypothesis. Neurology 43:1173\u20131180","journal-title":"Neurology"},{"key":"1251_CR8","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","volume":"69","author":"KC Simon","year":"2007","unstructured":"Simon KC, Chen H, Schwarzschild M et al (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688\u20131695","journal-title":"Neurology"},{"key":"1251_CR9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2010.03.002","volume":"293","author":"Y Miyake","year":"2010","unstructured":"Miyake Y, Tanaka K, Fukushima W et al (2010) Fukuoka Kinki Parkinson\u2019s Disease Study Group. Case-control study of risk of Parkinson\u2019s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 293:82\u201386","journal-title":"J Neurol Sci"},{"key":"1251_CR10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/HYPERTENSIONAHA.111.171249","volume":"57","author":"C Qiu","year":"2011","unstructured":"Qiu C, Hu G, Kivipelto M et al (2011) Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease: the National FINRISK Study. Hypertension 57:1094\u20131100","journal-title":"Hypertension"},{"key":"1251_CR11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0733-8651(01)00005-4","volume":"20","author":"I Biaggioni","year":"2002","unstructured":"Biaggioni I, Robertson RM (2002) Hypertension in orthostatic hypotension and autonomic dysfunction. Cardiol Clin 20:291\u2013301","journal-title":"Cardiol Clin"},{"key":"1251_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.HYP.0000081216.11623.C3","volume":"42","author":"DS Goldstein","year":"2003","unstructured":"Goldstein DS, Pechnik S, Holmes C et al (2003) Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42:136\u2013142","journal-title":"Hypertension"},{"key":"1251_CR13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/10641969409067946","volume":"16","author":"M Pirpiris","year":"1994","unstructured":"Pirpiris M, Cox H, Esler M et al (1994) Mineralocorticoid induced hypertension and noradrenaline spillover in man. Clin Exp Hypertens 16:147\u2013161","journal-title":"Clin Exp Hypertens"},{"key":"1251_CR14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R et al (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277:1046\u20131051","journal-title":"JAMA"},{"key":"1251_CR15","first-page":"494","volume":"43","author":"KF Tipton","year":"1997","unstructured":"Tipton KF (1997) Monoamine oxidase inhibitors and pressor response to dietary amines. Vopr Med Khim 43:494\u2013503","journal-title":"Vopr Med Khim"},{"key":"1251_CR16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1034\/j.1600-0404.2001.104002092.x","volume":"104","author":"GR Sigurdard\u00f3ttir","year":"2001","unstructured":"Sigurdard\u00f3ttir GR, Nilsson C, Odin P et al (2001) Cardiovascular effects of domperidone in patients with Parkinson\u2019s disease treated with apomorphine. Acta Neurol Scand 104:92\u201396","journal-title":"Acta Neurol Scand"},{"key":"1251_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1524-6175.2001.00516.x","volume":"4","author":"J Jordan","year":"2002","unstructured":"Jordan J, Biaggioni I (2002) Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens 4:139\u2013145","journal-title":"J Clin Hypertens"},{"key":"1251_CR18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1586\/14737175.6.8.1173","volume":"6","author":"A Pathak","year":"2006","unstructured":"Pathak A, Senard JM (2006) Blood pressure disorders during Parkinson\u2019s disease: epidemiology, pathophysiology and management. Expert Rev Neurother 6:1173\u20131180","journal-title":"Expert Rev Neurother"},{"key":"1251_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejim.2006.02.020","volume":"17","author":"AA Ejaz","year":"2006","unstructured":"Ejaz AA, Sekhon IS, Munjal S (2006) Characteristic findings on 24\u00a0h ambulatory blood pressure monitoring in a series of patients with Parkinson\u2019s disease. Eur J Intern Med 17:417\u2013420","journal-title":"Eur J Intern Med"},{"key":"1251_CR20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1524-6175.2007.07298.x","volume":"9","author":"AA Ejaz","year":"2007","unstructured":"Ejaz AA, Kazory A, Heinig ME (2007) 24\u00a0hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens 9:952\u2013955","journal-title":"J Clin Hypertens"},{"key":"1251_CR21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A et al (2007) ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25:1751\u20131762","journal-title":"J Hypertens"},{"key":"1251_CR22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/00004872-200109000-00004","volume":"19","author":"C Cuspidi","year":"2001","unstructured":"Cuspidi C, Macca G, Sampieri L et al (2001) Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 19:1539\u20131545","journal-title":"J Hypertens"},{"key":"1251_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajh.2009.187","volume":"23","author":"I Hajjar","year":"2010","unstructured":"Hajjar I, Zhao P, Alsop D et al (2010) Association of blood pressure elevation and nocturnal dipping with brain atrophy, perfusion and functional measures in stroke and non stroke individuals. Am J Hypertens 23:17\u201323","journal-title":"Am J Hypertens"},{"key":"1251_CR24","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/mds.22767","volume":"24","author":"C Schmidt","year":"2009","unstructured":"Schmidt C, Berg D, Herting et al (2009) Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 24:2136\u20132142","journal-title":"Mov Disord"},{"key":"1251_CR25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/08037051.2011.587280","volume":"20","author":"C Cuspidi","year":"2011","unstructured":"Cuspidi C, Sala C, Valerio C et al (2011) Nocturnal blood pressure in untreated essential hypertensives. Blood Press 20:335\u2013341","journal-title":"Blood Press"},{"key":"1251_CR26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3949\/ccjm.77a.09103","volume":"77","author":"M Wimbiscus","year":"2010","unstructured":"Wimbiscus M, Kostenko O, Malone D (2010) MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 77:859\u2013882","journal-title":"Cleve Clin J Med"},{"key":"1251_CR27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.HYP.0000188052.69549.e4","volume":"46","author":"DS Goldstein","year":"2005","unstructured":"Goldstein DS, Eldadah BA, Holmes C et al (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46:1333\u20131339","journal-title":"Hypertension"},{"key":"1251_CR28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2362.1990.tb01909.x","volume":"20","author":"JM Senard","year":"1990","unstructured":"Senard JM, Valet P, Durrieu G et al (1990) Adrenergic super-sensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest 20:613\u2013619","journal-title":"Eur J Clin Invest"},{"key":"1251_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00002512-200118070-00003","volume":"18","author":"JM Senard","year":"2001","unstructured":"Senard JM, Brefel-Courbon C, Rascol O et al (2001) Orthostatic hypotension in patients with Parkinson\u2019s disease: pathophysiology and management. Drugs Aging 18:495\u2013505","journal-title":"Drugs Aging"},{"key":"1251_CR30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/10641969409072223","volume":"16","author":"M Galinier","year":"1994","unstructured":"Galinier M, Senard JM, Valet P et al (1994) Relationship between arterial blood pressure disturbances and alpha adrenoceptor density. Clin Exp Hypertens 16:373\u2013389","journal-title":"Clin Exp Hypertens"},{"key":"1251_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01819025","volume":"5","author":"CJ Mathias","year":"1995","unstructured":"Mathias CJ (1995) The classification and nomenclature of autonomic disorders: ending chaos, resolving conflict and hopefully achieving clarity. Clin Autonom Res 5:307\u2013310","journal-title":"Clin Autonom Res"},{"key":"1251_CR32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.RES.73.2.367","volume":"73","author":"TN Jacobsen","year":"1993","unstructured":"Jacobsen TN, Morgan BJ, Scherrer U et al (1993) Relative contributions of cardiopulmonary and sinoaortic baroreflexes in causing sympathetic activation in the human skeletal muscle circulation during orthostatic stress. Circ Res 73:367\u2013378","journal-title":"Circ Res"},{"key":"1251_CR33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/01.WNL.0000052690.91036.FF","volume":"60","author":"Y Sharabi","year":"2003","unstructured":"Sharabi Y, Li ST, Dendi R et al (2003) Neurotransmitter specificity of sympathetic denervation in Parkinson\u2019s disease. Neurology 60:1036\u20131039","journal-title":"Neurology"},{"key":"1251_CR34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(03)00555-6","volume":"2","author":"DS Goldstein","year":"2003","unstructured":"Goldstein DS (2003) Dysautonomia in Parkinson\u2019s disease: neurocardiological abnormalities. Lancet Neurol 2:669\u2013676","journal-title":"Lancet Neurol"},{"key":"1251_CR35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1212\/WNL.58.8.1247","volume":"58","author":"DS Goldstein","year":"2002","unstructured":"Goldstein DS, Holmes C, Dendi R et al (2002) Orthostatic hypotension from sympathetic denervation in Parkinson\u2019s disease. Neurology 58:1247\u20131255","journal-title":"Neurology"},{"key":"1251_CR36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1097\/00004872-200309000-00017","volume":"21","author":"A Diedrich","year":"2003","unstructured":"Diedrich A, Jordan J, Tank J et al (2003) The sympathetic nervous system in hypertension: assessment by blood pressure variability and ganglionic blockade. J Hypertens 21:1677\u20131686","journal-title":"J Hypertens"},{"key":"1251_CR37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.HYP.0000250939.71343.7c","volume":"49","author":"F Barbic","year":"2007","unstructured":"Barbic F, Perego F, Canesi M et al (2007) Early abnormalities of vascular and cardiac autonomic control in Parkinson\u2019s disease without orthostatic hypotension. Hypertension 49:120\u2013126","journal-title":"Hypertension"},{"key":"1251_CR38","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C et al (2009) PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord 24:1641\u20131649","journal-title":"Mov Disord"},{"key":"1251_CR39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.STR.0000217384.03237.9c","volume":"37","author":"G Scigliano","year":"2006","unstructured":"Scigliano G, Musicco M, Soliveri P et al (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case\u2013control study. Stroke 37:1184\u20131188","journal-title":"Stroke"},{"key":"1251_CR40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/oxfordjournals.aje.a116960","volume":"139","author":"A Grandinetti","year":"1994","unstructured":"Grandinetti A, Morens DM, Reed D et al (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson\u2019s disease. Am J Epidemiol 139:1129\u20131138","journal-title":"Am J Epidemiol"},{"issue":"10","key":"1251_CR41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2377-10-95","volume":"19","author":"P Hoyo del","year":"2010","unstructured":"del Hoyo P, Garc\u00eda-Redondo A, de Bustos F et al (2010) Oxidative stress in skin fibroblasts cultures from patients with Parkinson\u2019s disease. BMC Neurol 19(10):95","journal-title":"BMC Neurol"},{"key":"1251_CR42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e3181ff9685","volume":"75","author":"H Mortiboys","year":"2010","unstructured":"Mortiboys H, Johansen KK, Aasly JO et al (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017\u20132020","journal-title":"Neurology"},{"key":"1251_CR43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0079-6123(10)84006-3","volume":"184","author":"CJ Barnum","year":"2010","unstructured":"Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson\u2019s disease. Prog Brain Res 184:113\u2013132","journal-title":"Prog Brain Res"},{"key":"1251_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN, Sanchez-Padilla J, Wokosin D et al (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:696\u2013700","journal-title":"Nature"},{"key":"1251_CR45","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/mds.23308","volume":"25","author":"T Simuni","year":"2010","unstructured":"Simuni T, Borushko E, Avram MJ et al (2010) Tolerability of isradipine in early Parkinson\u2019s disease: a pilot dose escalation study. Mov Disord 25:2863\u20132866","journal-title":"Mov Disord"},{"key":"1251_CR46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2006.03.004","volume":"51","author":"A Munoz","year":"2006","unstructured":"Munoz A, Rey P, Guerra MJ et al (2006) Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51:112\u2013120","journal-title":"Neuropharmacology"},{"key":"1251_CR47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","volume":"67","author":"B Ritz","year":"2010","unstructured":"Ritz B, Rhodes SL, Qian L et al (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67:600\u2013606","journal-title":"Ann Neurol"},{"key":"1251_CR48","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan CS, Guzman JN, Ilijic E et al (2007) Rejuvenation protects neurons in mouse models of Parkinson\u2019s disease. Nature 447:1081\u20131086","journal-title":"Nature"},{"key":"1251_CR49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00003495-199957060-00001","volume":"57","author":"RL Rodnitzky","year":"1999","unstructured":"Rodnitzky RL (1999) Can calcium antagonists provide a neuroprotective effect in Parkinson\u2019s disease? Drugs 57:845\u2013849","journal-title":"Drugs"},{"key":"1251_CR50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/106002809502900113","volume":"29","author":"JR Daniel","year":"1995","unstructured":"Daniel JR, Mauro VF (1995) Extrapyramidal symptoms associated with calcium channel blockers. Ann Pharmacother 29:73\u201375","journal-title":"Ann Pharmacother"},{"key":"1251_CR51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002826-199510000-00004","volume":"18","author":"MA Mena","year":"1995","unstructured":"Mena MA, Garcia de Yebenes MJ, Tabernero C et al (1995) Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 18:410\u2013426","journal-title":"Clin Neuropharmacol"},{"key":"1251_CR52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","volume":"13","author":"TG Ton","year":"2007","unstructured":"Ton TG, Heckbert SR, Longstreth WT Jr et al (2007) Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease. Parkinsonism Relat Disord 13:165\u2013169","journal-title":"Parkinsonism Relat Disord"},{"key":"1251_CR53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","volume":"30","author":"KA Reardon","year":"2000","unstructured":"Reardon KA, Mendelsohn FA, Chai SY et al (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease. Aust NZ J Med 30:48\u201353","journal-title":"Aust NZ J Med"},{"key":"1251_CR54","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/mds.22461","volume":"24","author":"YP Chang","year":"2009","unstructured":"Chang YP, Shih PY (2009) A case of Parkinson\u2019s disease worsened by captopril: an unexpected adverse effect. Mov Disord 24:790","journal-title":"Mov Disord"},{"key":"1251_CR55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410320306","volume":"32","author":"AM Allen","year":"1992","unstructured":"Allen AM, MacGregor DP, Chai SY et al (1992) Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 32:339\u2013344","journal-title":"Ann Neurol"},{"issue":"414\u2013420","key":"1251_CR56","first-page":"90","volume":"118","author":"DC Brown","year":"1996","unstructured":"Brown DC, Steward LJ, Ge J, Barnes NM (1996) Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 118(414\u2013420):90","journal-title":"Br J Pharmacol"},{"key":"1251_CR57","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/mds.21945","volume":"23","author":"GR Sarma","year":"2008","unstructured":"Sarma GR, Kamath V, Mathew T et al (2008) A case of parkinsonism worsened by losartan: a probable new adverse effect. Mov Disord 23:1055","journal-title":"Mov Disord"},{"key":"1251_CR58","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","volume":"70","author":"C Becker","year":"2008","unstructured":"Becker C, Jick SS, Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70:1438\u20131444","journal-title":"Neurology"},{"key":"1251_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900020496","volume":"12","author":"LF Blob","year":"2007","unstructured":"Blob LF, Sharoky M, Campbell BJ et al (2007) Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6\u00a0mg\/24 h. CNS Spectr 12:25\u201334","journal-title":"CNS Spectr"},{"key":"1251_CR60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002018-199819010-00002","volume":"19","author":"EH Heinonen","year":"1998","unstructured":"Heinonen EH, Myllyl\u00e4 V (1998) Safety of selegiline (deprenyl) in the treatment of Parkinson\u2019s disease. Drug Saf 19:11\u201322","journal-title":"Drug Saf"},{"key":"1251_CR61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/HYPERTENSIONAHA.108.115873","volume":"52","author":"WB White","year":"2008","unstructured":"White WB, Salzman P (2008) Parkinson\u2019s Rasagiline: efficacy and Safety in the Treatment of Off Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension 52:587\u2013593","journal-title":"Hypertension"},{"key":"1251_CR62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1353-8020(00)00027-4","volume":"7","author":"A Rojo","year":"2001","unstructured":"Rojo A, Font\u00e1n A, Mena MA et al (2001) Tolcapone increases plasma catecholamine levels in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 7:93\u201396","journal-title":"Parkinsonism Relat Disord"},{"key":"1251_CR63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/pgmj.2005.037457","volume":"82","author":"JE Naschitz","year":"2006","unstructured":"Naschitz JE, Slobodin G, Elias N, Rosner I (2006) The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J 82:246\u2013253","journal-title":"Postgrad Med J"},{"key":"1251_CR64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjhyper.2005.09.019","volume":"19","author":"GA Mansoor","year":"2006","unstructured":"Mansoor GA (2006) Orthostatic hypotension due to autonomic disorders in the hypertension clinic. Am J Hypertens 19:319\u2013326","journal-title":"Am J Hypertens"},{"key":"1251_CR65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/01.HYP.0000158835.94916.0c","volume":"45","author":"C Shibao","year":"2005","unstructured":"Shibao C, Gamboa A, Diedrich A et al (2005) Management of hypertension in the setting of autonomic failure: a pathophysiological approach. Hypertension 45:469\u2013476","journal-title":"Hypertension"},{"key":"1251_CR66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.HYP.0000199982.71858.11","volume":"47","author":"C Shibao","year":"2006","unstructured":"Shibao C, Gamboa A, Abraham R et al (2006) Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47:522\u2013526","journal-title":"Hypertension"},{"key":"1251_CR67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1681\/ASN.V10135","volume":"10","author":"J Jordan","year":"1999","unstructured":"Jordan J, Shannon JR, Pohar B et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10:35","journal-title":"J Am Soc Nephrol"},{"key":"1251_CR68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/eurheartj\/11.suppl_A.56","volume":"11","author":"J Mehlsen","year":"1990","unstructured":"Mehlsen J, Trap-Jensen J (1990) Haemodynamics in postural hypotension\u2014effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol. Eur Heart J 11:56\u201358","journal-title":"Eur Heart J"},{"key":"1251_CR69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","volume":"21","author":"R Freeman","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69\u201372","journal-title":"Clin Auton Res"},{"key":"1251_CR70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0735-1097(00)01062-7","volume":"37","author":"O Oldenburg","year":"2001","unstructured":"Oldenburg O, Mitchell A, Nurnberger J et al (2001) Ambulatory norepinephrine treatment of severe autonomic orthostatic hypotension. J Am Coll Cardiol 37:219\u2013223","journal-title":"J Am Coll Cardiol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-1251-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-012-1251-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-1251-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T04:57:44Z","timestamp":1714625864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-012-1251-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,30]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1007\/s10072-012-1251-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,30]]}}}